CLOs on the Move

GlucoTec

www.glucotec.com

 
GlucoTec is a Greenville, SC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million

Executives

Name Title Contact Details

Similar Companies

medical devicelink

medical devicelink is a West Palm Beach, FL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Ideal Protein

The Ideal Protein Method is medically designed & developed, being consistent with evidence-based guidelines for weight loss management and maintenance. It is a weight loss solution for the obese and overweight patient, including those with metabolic syndrome. Ideal Protein puts forward a proven, four-part method that enables safe, effective weight loss, with a healthy lifestyle approach and a structured maintenance program to sustain weight loss success. The method targets the root causes of weight gain by reversing the imbalance of insulin that occurs with the typical Western diet. A healthier lifestyle education is a key component of all phases of the Ideal Protein Weight Loss Method, which features personalized, one-on-one coaching and a diet plan to promote losing fat while maintaining lean muscle mass. For a hospital, medical group or private medical practice, the Ideal Protein Method is a comprehensive turnkey program with no costs for training and implementation, and no long-term commitment. Offered through healthcare practitioners, trained clinics and centers, the Ideal Protein Weight Loss Method and products are now available in more than 3,000 clinics and centers throughout North America. Research demonstrating the results of the Ideal Protein Weight Loss Method has been presented at leading medical conferences such as the 9th Annual Obesity Summit at the Cleveland Clinic and the Annual Scientific Meeting of the National Obesity Society. For information on Ideal Protein, please visit our website. For details about incorporating Ideal Protein into your medical practice, visit our practitioner information pages for Physicians and Pharmacists.

Gentis Inc

Gentis Inc is a Wayne, PA-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

XACT Robotics

XACT Robotics® is a privately held company focused on advancing the field of radiology by developing the world`s first and only hands-free robotic solutions that can significantly improve targeting accuracy, efficiency, and consistency in percutaneous radiology procedures. The company was founded in 2013 by Harel Gadot, a renowned entrepreneur in the MedTech robotics space, whose vision reimagined how image-guided percutaneous procedures are performed. At XACT, we embrace the philosophy of collaboration, tenacity, and extreme ownership. Our family culture empowers and inspires as we partner, develop, and execute meaningful technologies to make a difference in the lives of patients. Our company`s leadership is comprised of start-up, robotic, and disruptive technology experts with deep knowledge, vast experience and the diverse leadership skills required in the robotic market.

Contego Medical

Contego Medical, founded in 2005, has developed a family of novel emboli protection devices. The main feature of each device is that the treatment portion (i.e., balloon or stent) is on the same catheter as the embolic protection device, thus coupling the two together. This device can act as an angioplasty balloon with an integrated emboli protection device. If a stent is mounted on the balloon, it can serve as a stent with an integrated emboli protection device. We know that embolization occurs with all angioplasty and stenting procedures. It is usually hard to predict which ones will result in clinical sequalae. Despite knowing that embolization is ubiquitous, embolic protection devices are not used in all procedures as they add complexity, time, and cost. Dedicated devices do not exist for renal intervention, although the majority of physicians say they would use one if it existed. Contego Medical’s family of embolic protection devices represent a paradigm shift in the treatment of cardiovascular disease.